Lupin has received an approval for the acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & Industries and its associates (subject to approval of their shareholders). The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the Vitamins, Minerals and Supplements category. The Board of Directors of the company at its meeting held on January 17, 2022, approved the same.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
